Oppenheimer Holdings, Inc. reiterated their hold rating on shares of Endo International PLC (NASDAQ:ENDP) in a research note issued to investors on Sunday, July 23rd.
ENDP has been the subject of several other reports. William Blair reissued a market perform rating on shares of Endo International PLC in a research report on Wednesday, June 14th. Stifel Nicolaus lowered Endo International PLC from a buy rating to a hold rating and reduced their price target for the stock from $22.00 to $15.00 in a research report on Friday, June 9th. Vetr raised Endo International PLC from a strong sell rating to a sell rating and set a $11.34 price target for the company in a research report on Wednesday, May 17th. Canaccord Genuity set a $14.00 price target on Endo International PLC and gave the stock a hold rating in a research report on Monday, May 22nd. Finally, BMO Capital Markets reissued a hold rating and issued a $15.00 price target on shares of Endo International PLC in a research report on Monday, May 1st. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of Hold and an average price target of $14.75.
Shares of Endo International PLC (NASDAQ:ENDP) traded up 1.04% during midday trading on Friday, reaching $8.72. The company had a trading volume of 5,294,100 shares. The stock’s market capitalization is $1.95 billion. The firm’s 50 day moving average price is $10.47 and its 200-day moving average price is $11.43. Endo International PLC has a 1-year low of $7.41 and a 1-year high of $24.93.
Endo International PLC (NASDAQ:ENDP) last issued its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.19. The business had revenue of $875.73 million during the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. Endo International PLC’s revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.86 EPS. Equities research analysts expect that Endo International PLC will post $3.52 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Endo International PLC (ENDP) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/08/18/endo-international-plc-endp-given-hold-rating-at-oppenheimer-holdings-inc-updated-updated-updated.html.
In related news, COO Terrance J. Coughlin bought 20,000 shares of the stock in a transaction dated Thursday, August 10th. The shares were purchased at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the purchase, the chief operating officer now directly owns 181,369 shares of the company’s stock, valued at $1,396,541.30. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Paul Campanelli bought 6,500 shares of the stock in a transaction dated Monday, August 14th. The stock was bought at an average price of $7.71 per share, for a total transaction of $50,115.00. Following the purchase, the chief executive officer now directly owns 213,620 shares of the company’s stock, valued at $1,647,010.20. The disclosure for this purchase can be found here. Insiders bought 36,000 shares of company stock worth $279,460 in the last 90 days. Company insiders own 0.50% of the company’s stock.
Hedge funds have recently modified their holdings of the company. First Quadrant L P CA bought a new stake in shares of Endo International PLC during the first quarter worth approximately $24,556,000. OppenheimerFunds Inc. increased its stake in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock worth $32,065,000 after buying an additional 1,857,678 shares during the last quarter. Norges Bank bought a new stake in shares of Endo International PLC during the fourth quarter worth approximately $26,929,000. Bank of New York Mellon Corp increased its stake in shares of Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock worth $25,345,000 after buying an additional 633,904 shares during the last quarter. Finally, Diamond Hill Capital Management Inc. bought a new stake in shares of Endo International PLC during the second quarter worth approximately $5,454,000. Hedge funds and other institutional investors own 92.27% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.
